Treatment-driven selection of chemoresistant Ewing sarcoma tumors with limited drug distribution.

[1]  Y. Pommier,et al.  BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers , 2020, Science Translational Medicine.

[2]  P. Sorensen,et al.  Ewing Sarcoma , 2020, Sarcomas.

[3]  Nicola D. Roberts,et al.  Rearrangement bursts generate canonical gene fusions in bone and soft tissue tumors , 2018, Science.

[4]  J. Mora,et al.  GEIS-21: a multicentric phase II study of intensive chemotherapy including gemcitabine and docetaxel for the treatment of Ewing sarcoma of children and adults: a report from the Spanish sarcoma group (GEIS) , 2017, British Journal of Cancer.

[5]  J. Mora,et al.  Targeted drug distribution in tumor extracellular fluid of GD2‐expressing neuroblastoma patient‐derived xenografts using SN‐38‐loaded nanoparticles conjugated to the monoclonal antibody 3F8 , 2017, Journal of controlled release : official journal of the Controlled Release Society.

[6]  E. de Álava,et al.  Multidrug resistance transporter profile reveals MDR3 as a marker for stratification of blastemal Wilms tumour patients , 2017, Oncotarget.

[7]  U. Dirksen,et al.  Trabectedin Followed by Irinotecan Can Stabilize Disease in Advanced Translocation-Positive Sarcomas with Acceptable Toxicity , 2016, Sarcoma.

[8]  E. Abdallah,et al.  MRP1 expression in CTCs confers resistance to irinotecan‐based chemotherapy in metastatic colorectal cancer , 2016, International journal of cancer.

[9]  J. Fletcher,et al.  ABC transporters as mediators of drug resistance and contributors to cancer cell biology. , 2016, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[10]  J. Mora,et al.  SN-38-loaded nanofiber matrices for local control of pediatric solid tumors after subtotal resection surgery. , 2016, Biomaterials.

[11]  S. Hanash,et al.  Carboxylesterase 2 as a Determinant of Response to Irinotecan and Neoadjuvant FOLFIRINOX Therapy in Pancreatic Ductal Adenocarcinoma. , 2015, Journal of the National Cancer Institute.

[12]  Sven Rahmann,et al.  Mutational dynamics between primary and relapse neuroblastomas , 2015, Nature Genetics.

[13]  Elizabeth J. Osterlund,et al.  Molecular Pathways: Leveraging the BCL-2 Interactome to Kill Cancer Cells—Mitochondrial Outer Membrane Permeabilization and Beyond , 2015, Clinical Cancer Research.

[14]  J. Mora,et al.  Combined Microdialysis-Tumor Homogenate Method for the Study of the Steady State Compartmental Distribution of a Hydrophobic Anticancer Drug in Patient-Derived Xenografts , 2015, Pharmaceutical Research.

[15]  D. Gisselsson,et al.  Neuroblastoma patient-derived orthotopic xenografts retain metastatic patterns and geno- and phenotypes of patient tumours , 2014, International journal of cancer.

[16]  A. McKenna,et al.  The genomic landscape of pediatric Ewing sarcoma. , 2014, Cancer discovery.

[17]  Samy Lamouille,et al.  Molecular mechanisms of epithelial–mesenchymal transition , 2014, Nature Reviews Molecular Cell Biology.

[18]  Steven J. M. Jones,et al.  Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent Glioma , 2014, Science.

[19]  Y. Pommier,et al.  Dual Targeting of EWS-FLI1 Activity and the Associated DNA Damage Response with Trabectedin and SN38 Synergistically Inhibits Ewing Sarcoma Cell Growth , 2013, Clinical Cancer Research.

[20]  I. Tannock,et al.  Distribution of the anticancer drugs doxorubicin, mitoxantrone and topotecan in tumors and normal tissues , 2013, Cancer Chemotherapy and Pharmacology.

[21]  R. Boldrini,et al.  Expression of multidrug resistance-associated proteins in paediatric soft tissue sarcomas before and after chemotherapy. , 2012, International journal of oncology.

[22]  Mark T. W. Ebbert,et al.  Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes , 2011, Nature Medicine.

[23]  C. Waters,et al.  Tyrosine kinase inhibitor gefitinib enhances topotecan penetration of gliomas. , 2010, Cancer research.

[24]  C. Waters,et al.  Compartment-specific roles of ATP-binding cassette transporters define differential topotecan distribution in brain parenchyma and cerebrospinal fluid. , 2009, Cancer research.

[25]  M. Fukuzawa,et al.  Increased expression of multidrug resistance-associated genes after chemotherapy in pediatric solid malignancies. , 2009, Journal of pediatric surgery.

[26]  S. Burchill,et al.  Ploidy and karyotype complexity are powerful prognostic indicators in the Ewing's sarcoma family of tumors: A study by the United Kingdom Cancer Cytogenetics and the Children's Cancer and Leukaemia Group , 2008, Genes, chromosomes & cancer.

[27]  M Beth McCarville,et al.  Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma , 2007, Pediatric blood & cancer.

[28]  I. Tannock,et al.  Drug penetration in solid tumours , 2006, Nature Reviews Cancer.

[29]  R. Cozza,et al.  High histologic and overall response to dose intensification of ifosfamide, carboplatin, and etoposide with cyclophosphamide, doxorubicin, and vincristine in patients with high‐risk ewing sarcoma family tumors , 2006, Cancer.

[30]  Aiman Abrahim,et al.  Combined PET and microdialysis for in vivo assessment of intracellular drug pharmacokinetics in humans. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[31]  M. Ladanyi,et al.  Ewing sarcomas with p53 mutation or p16/p14ARF homozygous deletion: a highly lethal subset associated with poor chemoresponse. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  Peter J Houghton,et al.  Gefitinib Enhances the Antitumor Activity and Oral Bioavailability of Irinotecan in Mice , 2004, Cancer Research.

[33]  S. Donaldson,et al.  Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide--a Children's Cancer Group and Pediatric Oncology Group study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  P. Houghton,et al.  Imatinib Mesylate Is a Potent Inhibitor of the ABCG2 (BCRP) Transporter and Reverses Resistance to Topotecan and SN-38 in Vitro , 2004, Cancer Research.

[35]  A. Huvos,et al.  Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adults. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  A. Guo,et al.  Intestinal transport of irinotecan in Caco-2 cells and MDCK II cells overexpressing efflux transporters Pgp, cMOAT, and MRP1. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[37]  T. Merchant,et al.  Survival after recurrence of Ewing Tumors , 2002, Cancer.

[38]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[39]  M. Bernstein,et al.  Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  K. Kuroiwa,et al.  MDR1 gene overexpression and altered degree of methylation at the promoter region in bladder cancer during chemotherapeutic treatment. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[41]  P. Houghton,et al.  Efficacy of systemic administration of irinotecan against neuroblastoma xenografts. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[42]  Yanfeng Wang,et al.  The Simultaneous Estimation of the Influx and Efflux Blood-Brain Barrier Permeabilities of Gabapentin Using a Microdialysis-Pharmacokinetic Approach , 1996, Pharmaceutical Research.

[43]  S. Steinberg,et al.  Immunohistochemical detection of P-glycoprotein in Ewing's sarcoma and peripheral primitive neuroectodermal tumors before and after chemotherapy. , 1994, American journal of clinical pathology.

[44]  T. Tsuruo,et al.  Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody. , 1990, Cancer research.

[45]  J. Mora,et al.  Treatment of relapsed/refractory pediatric sarcomas with gemcitabine and docetaxel. , 2009, Journal of pediatric hematology/oncology.